• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Azitra Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    7/26/24 4:05:15 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZTR alert in real time by email
    false 0001701478 0001701478 2024-07-23 2024-07-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): July 23, 2024

     

     

     

    AZITRA, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-41705   46-4478536

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    21 Business Park Drive

    Branford, CT 06405

     
    (Address of principal executive offices)(Zip Code)

     

    (203) 646-6446
    (Registrant’s telephone number, including area code)

     

     

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock: Par value $0.0001   AZTR   NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    The information regarding the Securities Purchase Agreement, Agency Agreement and Warrant Agent Agreement (as defined below) set forth in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.

     

    Item 8.01 Other Events.

     

    On July 25, 2024, Azitra, Inc., a Delaware corporation (the “Company”), completed a public offering (the “Offering”) of (i) 6,665,000 shares (the “Common Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”); and (ii) Class A Warrants (the “Class A Warrants”) exercisable for an aggregate of 13,330,000 shares of Common Stock (the “Class A Warrant Shares”) issued pursuant to a securities purchase agreement, dated July 23, 2024 (the “Securities Purchase Agreement”), between the Company and certain institutional investors named therein and a Placement Agency Agreement dated July 23, 2024 (the “Agency Agreement”) between the Company and Maxim Group LLC, as placement agent.

     

    The offering price of each Common Share and accompanying Class A Warrants was $1.50.

     

    The Class A Warrants have an initial exercise price of $1.50 per share of Common Stock, however on the date that is 30 calendar days immediately following the date of issuance of the Class A Warrants, or August 24, 2024 (the “Reset Date”), if the Reset Price, as defined below, is less than the exercise price at such time, the exercise price will be decreased to the Reset Price. “Reset Price” shall mean 100% of the trailing five-day VWAP immediately preceding the Reset Date, provided, that in no event shall the Reset Price be less than $0.32 (subject to adjustment for reverse and forward stock splits, recapitalizations and similar transactions), which represents 20% of the most recent closing price for the Common Stock at the time of execution of the Agency Agreement. The number of shares of Common Stock issuable upon exercise of the Class A Warrants will not be proportionately adjusted in the event of a reset of the exercise price.

     

    The Class A Warrants are exercisable upon issuance and expire five years from the date of issuance. The Class A Warrants contain ownership limitations pursuant to which a holder does not have the right to exercise any portion of their warrants if it would result in the holder (together with its affiliates) beneficially owning more than 4.99% (or, at the election of the holder, 9.99%) of the Company’s outstanding Common Stock. The Class A Warrants are issued pursuant to a Warrant Agent Agreement dated July 25, 2024 (“Warrant Agent Agreement”) between the Company and VStock Transfer LLC, as warrant agent.

     

    In consideration for Maxim Group LLC serving as the placement agent of the Offering (the “Placement Agent”), the Company paid the Placement Agent a cash fee equal to 7% of the aggregate gross proceeds of the Offering and reimbursed the Placement Agent for certain expenses and legal fees up to $100,000. The Company also issued warrants to designees of the Placement Agent (the “Placement Agent Warrants”) exercisable for an aggregate of 266,600 shares of Common Stock (the “Placement Agent Warrant Shares”). The Placement Agent Warrants have substantially the same terms as the Class A Warrants, except that the Placement Agent Warrants have an exercise price equal to $1.875 per share (125% of the $1.50 offering price of the Common Share and accompanying Class A Warrants), have an initial exercise date of January 23, 2025 and expire on July 23, 2029.

     

    The Common Shares, Class A Warrants, Class A Warrant Shares, Placement Agent Warrant and Placement Agent Warrant Shares were offered pursuant to a registration statement on Form S-1 (File No. 333-280806), as amended, which was declared effective by the Securities and Exchange Commission (the “SEC”) on July 23, 2024.

     

    The Company received net proceeds of approximately $8.95 million from the Offering, after deducting Offering expenses payable by the Company, including the Placement Agent’s commissions and fees. The Company intends to use the net proceeds from the Offering for general corporate purposes, including working capital.

     

    Forms of the Agency Agreement, the Class A Warrant, Placement Agent Warrant, Warrant Agent Agreement and Securities Purchase Agreement are filed as Exhibits 1.1, 4.1, 4.2. 4.3 and 10.1 to this Current Report on Form 8-K and are incorporated by reference herein.

     

    On July 23, 2024, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    On July 25, 2024, the Company issued a press release announcing the closing of the Offering. A copy of the press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

     

    Item 9.01 Financial Statements and Exhibits

     

    (d) Exhibits   Method Filing

     

    The following exhibits are filed with this report:

     

    Exhibit 1.1  

    Placement Agency Agreement dated July 23, 2024 between the Registrant and Maxim Group LLC

      Filed electronically herewith
    Exhibit 4.1   Form of Class A Warrant   Filed electronically herewith
    Exhibit 4.2   Form of Placement Agent Warrant   Filed electronically herewith
    Exhibit 4.3   Warrant Agent Agreement dated July 25, 2024 between the Registrant and VStock Transfer LLC   Filed electronically herewith
    Exhibit 10.1   Form of Securities Purchase Agreement between the Registrant   Filed electronically herewith
    Exhibit 99.1   Press release dated July 23, 2024 announcing the pricing of the offering   Filed electronically herewith
    Exhibit 99.2   Press release dated July 25, 2024 announcing the closing of the offering   Filed electronically herewith
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document    

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      AZITRA, INC.
       
    Dated: July 25, 2024 /s/ Francisco D. Salva
      Francisco D. Salva
      Chief Executive Officer

     

     

    Get the next $AZTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AZTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Azitra, Inc. Announces Addition of MD Anderson Cancer Center as Clinical Site for Phase 1/2 Trial of ATR-04 Targeting EGFRi-Associated Skin Rash

    MD Anderson Cancer Center expands ATR-04 clinical trial site footprint, offering potential to accelerate enrollment and patient treatment milestonesBRANFORD, Conn., Feb. 24, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of The University of Texas MD Anderson Cancer Center as a clinical site for its ongoing Phase 1/2 clinical trial evaluating ATR-04 (ATR04-484). ATR-04 is a first-in-class, topically applied live biotherapeutic product candidate designed to treat EGFR inhibitor ("EGFRi")-associated rash.

    2/24/26 8:00:00 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra, Inc. to Present at BIO Investment & Growth Summit

    BRANFORD, Conn., Feb. 19, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it will present at the BIO Investment & Growth Summit taking place in Miami Beach, Florida, March 2-3, 2026. The presentation will highlight recent updates and progress in Azitra's pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome; ATR-04, being developed in a Phase 1/2 trial for the treatment of moderate to severe EG

    2/19/26 8:00:00 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

    BRANFORD, Conn., Feb. 6, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced its Special Meeting scheduled for and convened on February 6, 2026, (the "Special Meeting") has been adjourned until March 6, 2026, at 11:00 a.m. Eastern Time (the "Reconvened Special Meeting") for the purpose of soliciting additional votes with respect to the proposals outlined below and described in the Company's definitive proxy statement for the Special Meeting filed with the U.S. Securities and Exchange Commission (the "SEC") on January 2, 2026 (the "Special Meeting Proxy Statement") becau

    2/6/26 4:15:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Whitfill Travis

    4 - Azitra, Inc. (0001701478) (Issuer)

    12/22/25 5:28:27 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Staskey Norm

    4 - Azitra, Inc. (0001701478) (Issuer)

    12/22/25 5:28:23 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ryan Barbara

    4 - Azitra, Inc. (0001701478) (Issuer)

    12/22/25 5:28:24 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    SEC Filings

    View All

    SEC Form DEFA14A filed by Azitra Inc

    DEFA14A - Azitra, Inc. (0001701478) (Filer)

    2/6/26 4:17:06 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Azitra, Inc. (0001701478) (Filer)

    2/6/26 4:15:22 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Azitra Inc

    S-8 - Azitra, Inc. (0001701478) (Filer)

    1/30/26 4:05:35 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Staskey Norm bought $10,034 worth of shares (47,600 units at $0.21), increasing direct ownership by 1,360% to 51,100 units (SEC Form 4)

    4 - Azitra, Inc. (0001701478) (Issuer)

    4/1/24 9:51:59 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Leadership Updates

    Live Leadership Updates

    View All

    Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

    BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies. "We are delighted to welcome Travis back to Azitra full time, after his tenure of nearly ten years in biotech venture capital," said Francisco Salva, President and CEO of Azitra. "Travis brings a wealth of knowledge in biotech, synthetic biology, and drug development. He will

    7/11/23 4:05:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Financials

    Live finance-specific insights

    View All

    Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

    BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update. FY 2024 and Recent Business Highlights Initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients; Initial safety data from first set of Netherton syndrome patients expected in the first half of 2025 with topline data from the Phase 1b trial by year-end 2025Received clearance from the U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical stu

    2/24/25 8:30:00 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

    BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update. Q3 2024 and Recent Business Highlights: Completed a follow-on offering of $10 million in gross proceedsDosed first Netherton syndrome patient with ATR-12Submitted an IND to the FDA and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitorsReceived Fast Track designat

    11/12/24 5:05:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

    Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones Strengthened global intellectual property portfolio with newly granted and allowed patents Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting Pres

    8/12/24 6:23:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:56:51 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:18:21 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/6/24 4:35:43 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care